Björn Steffen

4.8k total citations
72 papers, 2.0k citations indexed

About

Björn Steffen is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Björn Steffen has authored 72 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Hematology, 20 papers in Molecular Biology and 19 papers in Oncology. Recurrent topics in Björn Steffen's work include Acute Myeloid Leukemia Research (31 papers), Chronic Myeloid Leukemia Treatments (11 papers) and Neutropenia and Cancer Infections (11 papers). Björn Steffen is often cited by papers focused on Acute Myeloid Leukemia Research (31 papers), Chronic Myeloid Leukemia Treatments (11 papers) and Neutropenia and Cancer Infections (11 papers). Björn Steffen collaborates with scholars based in Germany, United States and United Kingdom. Björn Steffen's co-authors include Hubert Serve, Wolfgang E. Berdel, Carsten Müller‐Tidow, Joachim Schwäble, Bülent Sargin, Lara Tickenbrock, Christian Brandts, Sven Diederichs, Ping Ji and Ralf Metzger and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Björn Steffen

71 papers receiving 2.0k citations

Peers

Countries citing papers authored by Björn Steffen

Since Specialization

Citations

This map shows the geographic impact of Björn Steffen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Björn Steffen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Björn Steffen more than expected).

Fields of papers citing papers by Björn Steffen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Björn Steffen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Björn Steffen. The network helps show where Björn Steffen may publish in the future.

Co-authorship network of co-authors of Björn Steffen

This figure shows the co-authorship network connecting the top 25 collaborators of Björn Steffen. A scholar is included among the top collaborators of Björn Steffen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Björn Steffen. Björn Steffen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Real‐world effectiveness of first‐line azacitidine or decitabine with or without venetoclax in acute myeloid leukemia patients unfit for intensive therapy 2024 ·European Journal Of Haematology ·(unknown), Jörg Chromik, (unknown), Sebastian Wolf, (unknown), (unknown), Julius C. Enßle, (unknown), Martin Sebastian, Björn Steffen, Thomas Oellerich, Hubert Serve, Andreas Neubauer, Jonas Schäfer, Joerg Thomas Bittenbring	4
2	Central nervous system relapse after allogeneic HCT in FLT3-mutated AML 2024 ·Annals of Hematology ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Fabian Lang, Björn Steffen, Thomas Oellerich, Hubert Serve, Anjali Cremer, Gesine Bug	0
3	Update on GMALL Trial 08/2013 Shows Durable Favorable Outcome of Newly Diagnosed Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) with Imatinib, Dose-Reduced Induction Followed By Stem Cell Transplantation 2024 ·Blood ·Roman Pfeifer, Fabian Lang, Walter Fiedler, Matthias Stelljes, Folker Schneller, Björn Steffen, Boris Böll, Andreas Viardot, Christoph Faul, Lino L. Teichmann, Hendrik Poeck, Joerg Westermann, Kerstin Schäfer‐Eckart, Thomas Heinicke, Thomas Burmeister, Stefan Schwartz, Monika Brüggemann, Hubert Serve, Nicola Goekbuget	2
4	Treatment with midostaurin and other FLT3 targeting inhibitors is associated with an increased risk of cardiovascular adverse events in patients who underwent allogeneic hematopoietic stem cell transplantation with FLT3-mutated AML 2023 ·Annals of Hematology ·Anjali Cremer, Julius C. Enßle, (unknown), (unknown), Fabian Lang, Christian Brandts, Andreas M. Zeiher, Sebastian Cremer, Björn Steffen, Hubert Serve, Gesine Bug	2
5	A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy 2022 ·Annals of Hematology ·(unknown), Raphael Koch, Joachim Gerß, Marcus Hentrich, Rudolf Peceny, Tobias Bartscht, Björn Steffen, (unknown), Karsten Spiekermann, Linus Angenendt, Jan‐Henrik Mikesch, (unknown), Trude Butterfaß‐Bahloul, Hubert Serve, Georg Lenz, Wolfgang E. Berdel, Utz Krug, Christoph Schliemann	1
6	Acute kidney injury adversely affects the clinical course of acute myeloid leukemia patients undergoing induction chemotherapy 2021 ·Annals of Hematology ·(unknown), (unknown), Stefan Büttner, Jan Stratmann, (unknown), Uta Brunnberg, (unknown), Björn Steffen, Sebastian Wagner, Fabian Finkelmeier, Hubert Serve, Christian Brandts	6
7	Fluid overload is associated with increased 90-day mortality in AML patients undergoing induction chemotherapy 2021 ·Annals of Hematology ·(unknown), (unknown), Sebastian E. Koschade, Stefan Büttner, Jan Stratmann, Uta Brunnberg, (unknown), Franziska Frank, Sebastian Wagner, Björn Steffen, Hubert Serve, Fabian Finkelmeier, Christian Brandts	3
8	Blast vacuolization in AML patients indicates adverse-risk AML and is associated with impaired survival after intensive induction chemotherapy 2019 ·PLoS ONE ·(unknown), Jan Stratmann, Hubert Serve, Björn Steffen, Fabian Finkelmeier, Christian Brandts	7
9	Bloodstream infections with vancomycin-resistant enterococci are associated with a decreased survival in patients with hematological diseases 2019 ·Annals of Hematology ·Sarah Weber, Michael Hogardt, Claudia Reinheimer, Thomas A. Wichelhaus, Volkhard A. J. Kempf, Johanna Kessel, Sebastian Wolf, Hubert Serve, Björn Steffen, Sebastian Scheich	28
10	CD20 Expression and Response to Rituximab Treatment in B-Cell Precursor Lymphoblastic Leukemia - Results of the GMALL 08/2013 Trial 2018 ·Blood ·Monika Szczepanowski, Johanna Richter, (unknown), Matthias Ritgen, Heiko Trautmann, Henrik Knecht, Mustafa Kondakci, Christoph Faul, Björn Steffen, Andreas Viardot, Michael Kneba, Dieter Hoelzer, Nicola Goekbuget, Monika Brüggemann	3
11	Bloodstream infections with gram-negative organisms and the impact of multidrug resistance in patients with hematological malignancies 2018 ·Annals of Hematology ·Sebastian Scheich, Sarah Weber, Claudia Reinheimer, Thomas A. Wichelhaus, Michael Hogardt, Volkhard A. J. Kempf, Johanna Kessel, Hubert Serve, Björn Steffen	33
12	Clinical Impact of Colonization with Multidrug-Resistant Organisms on Outcome after Autologous Stem Cell Transplantation: A Retrospective Single-Center Study 2017 ·Biology of Blood and Marrow Transplantation ·Sebastian Scheich, Claudia Reinheimer, Christian Brandt, Thomas A. Wichelhaus, Michael Hogardt, Volkhard A. J. Kempf, Uta Brunnberg, Christian Brandts, (unknown), Ivana von Metzler, Johanna Kessel, Hubert Serve, Björn Steffen	31
13	Phase 3 study of quizartinib (AC220) monotherapy vs salvage chemotherapy (SC) in patients (pts) with FLT3-ITD+ acute myeloid leukemia (AML) refractory to or relapsed (R/R) after 1st-line treatment with or without hematopoietic stem cell transplant (HSCT) consolidation: the QuANTUM-R study 2016 ·Annals of Oncology ·Jörge E. Cortes, Guy Gammon, Samer K. Khaled, Giovanni Martinelli, Amy Kramer, Björn Steffen, Donna E. Hogge, Brian A. Jonas, Hervé Dombret, Alexander E. Perl	3
14	On the advice complexity of the online L(2,1)-coloring problem on paths and cycles 2014 ·Theoretical Computer Science ·(unknown), Hans-Joachim Böckenhauer, Juraj Hromkovič, (unknown), Björn Steffen	5
15	Fehlerkorrigierende Codes - Ein Unterrichtsbeispiel zum gelenkten entdeckenden Lernen. 2011 ·Juraj Hromkovič, (unknown), Dennis Komm, (unknown), Björn Steffen	1
16	Steiner tree reoptimization in graphs with sharpened triangle inequality 2011 ·Journal of Discrete Algorithms ·Hans-Joachim Böckenhauer, (unknown), Juraj Hromkovič, Tobias Mömke, (unknown), Björn Steffen	3
17	The molecular pathogenesis of acute myeloid leukemia 2005 ·Critical Reviews in Oncology/Hematology ·Björn Steffen, Carsten Müller‐Tidow, Joachim Schwäble, Wolfgang E. Berdel, Hubert Serve	60
18	S100 Family Members and Trypsinogens Are Predictors of Distant Metastasis and Survival in Early-Stage Non-Small Cell Lung Cancer 2004 ·Cancer Research ·Sven Diederichs, Etmar Bulk, Björn Steffen, Ping Ji, Lara Tickenbrock, Kerstin Lang, Kurt S. Zänker, Ralf Metzger, Paul M. Schneider, Volker Gerke, Michael Thomas, Wolfgang E. Berdel, Hubert Serve, Carsten Müller‐Tidow	168
19	Expression of the p14ARF tumor suppressor predicts survival in acute myeloid leukemia 2004 ·Leukemia ·Carsten Müller‐Tidow, (unknown), Horst Buerger, Jens Packeisen, (unknown), Gerhard Heil, (unknown), (unknown), Joachim Schwäble, Björn Steffen, WD Ludwig, Achim Heinecke, Th. Büchner, Wolfgang E. Berdel, Hubert Serve	24
20	Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations 2003 ·Blood ·Masao Mizuki, Joachim Schwäble, (unknown), Chunaram Choudhary, Shuchi Agrawal, Bülent Sargin, Björn Steffen, Itaru Matsumura, Yuzuru Kanakura, Frank D. Böhmer, Carsten Müller‐Tidow, Wolfgang E. Berdel, Hubert Serve	238

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact